[Clinical evaluation of aspoxicillin in children]

Aspoxicillin (ASPC), a new semisynthetic penicillin, was administered to a total of 13 children with respiratory tract and other various infections. Respiratory tract infections in 7 of 13 children were treated with ASPC intravenously, 64 to 144 mg/kg/day t.d.s. or q.i.d. The other 6 patients with various types of infections were also treated with the combination of ASPC and other antibiotics. Their clinical and laboratory data were evaluated only for adverse reactions. Concentration of ASPC level in serum and urine was determined after 60 minutes intravenous drip infusion of 20 mg/kg/dose of ASPC dissolved with the solution of solita T3 in 3 children. The half-life of ASPC was 0.76 to 2.31 hours and urinary excretion rate was 53.0% in first 6 hours. The effectiveness rate in respiratory tract infections was 100%. Clinical side effects were not recognized except loose stool in 1 case. The increase and decrease of platelet counts and the elevation of GPT were encountered 3 of 13 cases.